PROFESSIONAL CERTIFICATION EXAMINATION
Pharmacology Dosage Calculations & Drug Classifications:
Comprehensive Insulin Management Mastery (200 Questions)
Candidate Name: Date:
__________________________ ________________________
Score: _______ / 200 (______%) Passing Standard: 85%
(170/200)
EXAMINATION INSTRUCTIONS & GUIDELINES
1. EXAMINATION STRUCTURE: This comprehensive examination
contains 200 multiple-choice questions divided into four core clinical
domains: Insulin Pharmacokinetics & Pharmacodynamics (Q1–50),
Advanced Dosage Calculations & Titration Protocols (Q51–100),
Complex Clinical Scenarios & Complication Management (Q101–
150), and Safety, Pump Therapy, and Interprofessional Interventions
(Q151–200).
2. SCORING & PASSING CRITERIA: A minimum passing score of
85% (170 correct answers) is required to demonstrate clinical
competency in insulin management and dosage calculations.
3. CALCULATION PROTOCOLS: All calculation questions assume
standard clinical rounding rules (round to the nearest tenth for
decimal values unless otherwise specified; whole numbers for units of
insulin). Standard conversion factors apply (1 kg = 2.2 lbs; 1 unit =
standard U-100 concentration unless stated otherwise).
,4. RATIONALES: Detailed clinical rationales and pharmacological
mechanisms are provided in the answer key section following the
examination questions.
,SECTION 1: Insulin Pharmacokinetics, Pharmacodynamics &
Classifications (Questions 1–50)
Question 1: Which of the following describes the pharmacodynamic
profile of rapid-acting insulin analogues (e.g., Lispro, Aspart,
Glulisine)?
A. Onset 1–2 hours, peak 4–8 hours, duration 12–24 hours
B. Onset 10–15 minutes, peak 30–90 minutes, duration 3–5 hours
C. Onset 30–60 minutes, peak 2–4 hours, duration 5–8 hours
D. Onset 1–2 hours, peak flat, duration 24+ hours
Correct Answer: B
Rationale: Rapid-acting insulin analogues have an extremely fast
onset (10–15 minutes), peak activity within 30–90 minutes, and a
duration of action lasting 3–5 hours, closely mimicking physiologic
prandial insulin secretion.
Question 2: What is the primary mechanism of action of basal
insulin analogues such as insulin glargine (U-100) and detemir?
A. Rapid mucosal absorption stimulating immediate beta-cell
regeneration
B. Formation of micro-precipitates or subcutaneous binding to
albumin resulting in slow, continuous, peakless release
C. Inhibition of hepatic glycogen phosphorylase
D. Enhancement of renal glucose excretion via SGLT2 receptor
blockade
Correct Answer: B
Rationale: Insulin glargine precipitates at neutral physiological pH
in subcutaneous tissue, forming micro-precipitates that slowly
dissolve, providing a relatively peakless 24-hour basal profile.
Insulin detemir reversibly binds to albumin via its fatty acid chain.
, Question 3: A patient is prescribed Regular insulin (Humulin R,
Novolin R). What is the standard onset and peak time for
subcutaneous administration of Regular insulin?
A. Onset 5–10 mins, peak 30 mins
B. Onset 30–60 mins, peak 2–3 hours
C. Onset 1–2 hours, peak 6–12 hours
D. Onset 3–4 hours, peak 8–16 hours
Correct Answer: B
Rationale: Regular insulin is a short-acting human insulin with an
onset of 30–60 minutes, peak action between 2–3 hours (and
duration of 5–8 hours), requiring administration 30–45 minutes
prior to meals.
Question 4: Which insulin preparation has an onset of 1–2 hours, a
pronounced peak at 4–12 hours, and a duration of 18–24 hours,
traditionally requiring careful timing with meals to prevent late
postprandial hypoglycemia?
A. Insulin Aspart
B. Insulin Glargine U-300
C. Neutral Protamine Hagedorn (NPH) insulin
D. Insulin Degludec
Correct Answer: C
Rationale: NPH (Neutral Protamine Hagedorn) is an intermediate-
acting insulin combined with protamine to delay absorption. Its
pronounced peak (4–12 hours) creates a significant risk of
hypoglycemia if snacks or meals are delayed.
Question 5: Insulin degludec (Tresiba) is classified as an ultra-long-
acting basal insulin. What structural characteristic allows its
duration of action to extend beyond 42 hours?
Pharmacology Dosage Calculations & Drug Classifications:
Comprehensive Insulin Management Mastery (200 Questions)
Candidate Name: Date:
__________________________ ________________________
Score: _______ / 200 (______%) Passing Standard: 85%
(170/200)
EXAMINATION INSTRUCTIONS & GUIDELINES
1. EXAMINATION STRUCTURE: This comprehensive examination
contains 200 multiple-choice questions divided into four core clinical
domains: Insulin Pharmacokinetics & Pharmacodynamics (Q1–50),
Advanced Dosage Calculations & Titration Protocols (Q51–100),
Complex Clinical Scenarios & Complication Management (Q101–
150), and Safety, Pump Therapy, and Interprofessional Interventions
(Q151–200).
2. SCORING & PASSING CRITERIA: A minimum passing score of
85% (170 correct answers) is required to demonstrate clinical
competency in insulin management and dosage calculations.
3. CALCULATION PROTOCOLS: All calculation questions assume
standard clinical rounding rules (round to the nearest tenth for
decimal values unless otherwise specified; whole numbers for units of
insulin). Standard conversion factors apply (1 kg = 2.2 lbs; 1 unit =
standard U-100 concentration unless stated otherwise).
,4. RATIONALES: Detailed clinical rationales and pharmacological
mechanisms are provided in the answer key section following the
examination questions.
,SECTION 1: Insulin Pharmacokinetics, Pharmacodynamics &
Classifications (Questions 1–50)
Question 1: Which of the following describes the pharmacodynamic
profile of rapid-acting insulin analogues (e.g., Lispro, Aspart,
Glulisine)?
A. Onset 1–2 hours, peak 4–8 hours, duration 12–24 hours
B. Onset 10–15 minutes, peak 30–90 minutes, duration 3–5 hours
C. Onset 30–60 minutes, peak 2–4 hours, duration 5–8 hours
D. Onset 1–2 hours, peak flat, duration 24+ hours
Correct Answer: B
Rationale: Rapid-acting insulin analogues have an extremely fast
onset (10–15 minutes), peak activity within 30–90 minutes, and a
duration of action lasting 3–5 hours, closely mimicking physiologic
prandial insulin secretion.
Question 2: What is the primary mechanism of action of basal
insulin analogues such as insulin glargine (U-100) and detemir?
A. Rapid mucosal absorption stimulating immediate beta-cell
regeneration
B. Formation of micro-precipitates or subcutaneous binding to
albumin resulting in slow, continuous, peakless release
C. Inhibition of hepatic glycogen phosphorylase
D. Enhancement of renal glucose excretion via SGLT2 receptor
blockade
Correct Answer: B
Rationale: Insulin glargine precipitates at neutral physiological pH
in subcutaneous tissue, forming micro-precipitates that slowly
dissolve, providing a relatively peakless 24-hour basal profile.
Insulin detemir reversibly binds to albumin via its fatty acid chain.
, Question 3: A patient is prescribed Regular insulin (Humulin R,
Novolin R). What is the standard onset and peak time for
subcutaneous administration of Regular insulin?
A. Onset 5–10 mins, peak 30 mins
B. Onset 30–60 mins, peak 2–3 hours
C. Onset 1–2 hours, peak 6–12 hours
D. Onset 3–4 hours, peak 8–16 hours
Correct Answer: B
Rationale: Regular insulin is a short-acting human insulin with an
onset of 30–60 minutes, peak action between 2–3 hours (and
duration of 5–8 hours), requiring administration 30–45 minutes
prior to meals.
Question 4: Which insulin preparation has an onset of 1–2 hours, a
pronounced peak at 4–12 hours, and a duration of 18–24 hours,
traditionally requiring careful timing with meals to prevent late
postprandial hypoglycemia?
A. Insulin Aspart
B. Insulin Glargine U-300
C. Neutral Protamine Hagedorn (NPH) insulin
D. Insulin Degludec
Correct Answer: C
Rationale: NPH (Neutral Protamine Hagedorn) is an intermediate-
acting insulin combined with protamine to delay absorption. Its
pronounced peak (4–12 hours) creates a significant risk of
hypoglycemia if snacks or meals are delayed.
Question 5: Insulin degludec (Tresiba) is classified as an ultra-long-
acting basal insulin. What structural characteristic allows its
duration of action to extend beyond 42 hours?
